

Funding research. Fueling hope.

Made possible by the generosity of LCRF's supporters, the research we fund focuses on the areas of greatest need, tackles the most urgent questions, and accelerates progress toward improved survival, quality of life, and ultimately a **cure for lung cancer**. Lung cancer doesn't discriminate. If you have lungs, you can get lung cancer. Lung cancer still has the highest mortality of all cancers but receives the least amount of funding relative to its mortality rate.

For many patients with lung cancer, assuring they will have a second and third line of treatment is a race against time.

By expanding research funding and empowering investigators, LCRF **accelerates** the journey from **laboratory discovery to life-saving cures for patients**.

PREVENTION + EARLY DETECTION

David Adler, MD, MPH

University of Rochester

Increasing Lung Cancer Screening Uptake Among Emergency Department Patients



Crispin Hiley, MD, PhD

University College, London

Determinants of immune age and immune surveillance for early detection



Nicholas Juul, MD

Stanford University School of Medicine

Identifying biomarkers of precancerous copy number alteration in normal alveolar epithelium



Hilary Robbins, PhD

International Agency for Research on Cancer (IARC)

Lung cancer risk assessment for people who never smoked



LEADING EDGE RESEARCH GRANTS

Riyue Bao, PhD

The University of Pittsburgh

Radiomics to Decipher Patient & Organ Heterogeneity in Response to Immunotherapies in NSCLC



Joseph Chan, MD, PhD

Memorial Sloan Kettering

Biomarkers of Response & Toxicity to Tarlatamab in Patients with Metastatic SCLC



Tom Cunningham, PhD

The University of Cincinnati


Understanding the Dependency of RAS-driven Lung Adenocarcinomas on PRPS enzyme remodeling



Timothy Martin, PhD

University of Virginia School of Medicine, Charlottesville

Defining how UFMylation pathway inhibition enhances anti-lung tumor immunity



Patricia Pereira, PhD

Washington University School of Medicine, St. Louis

Antibody click for lung cancer therapy



John Prensner, MD, PhD

University of Michigan

Microproteins as novel disease targets in squamous cell lung cancer



Lu Wang, PhD

Northwestern University Feinberg College of Medicine

Therapeutic targeting of ASXL3 protein stability in small cell lung cancer



Joan H. Schiller, MD Award for Scientific Merit

Learn more about the research we're funding at [LCRF.org/currentresearch](https://www.lcrf.org/currentresearch).

OVERCOMING RESISTANCE

Dongsung Kim, PhD

Ohio State University

A novel targeted therapeutic strategy for KRAS inhibitor resistant lung cancers



Ximeng Liu, PhD

University of Texas MD

Deciphering response and resistance mechanisms to firmonertinib in NSCLC patients with EGFR PACC mutations



Chendi Li, PhD

Massachusetts General Hospital

Enhancing anti-tumor chemokines in KRAS G12C inhibitor-resistant NSCLC



I was once a young investigator who received seed funding through LCRF. Funding young investigators is key to keeping the smartest people in the field and coming up with new ideas of tomorrow."

Lecia Sequist, MD

Massachusetts General Hospital Cancer Center
Harvard Medical School
2010 LCRF Grantee

MINORITY CAREER DEVELOPMENT IN LUNG CANCER

Juliana Cazarin de Menezes, PhD

University of Rochester

Role of BMAL1 and Circadian Disruption in Modulating Tumor Immunity and Immunotherapy Response in Lung Adenocarcinoma



Nelson LaMarche, PhD

Yale School of Medicine

Defining clinically targetable drivers of pathogenic myeloid cell development for NSCLC immunotherapy



LCRF | BOEHRINGER INGELHEIM HER2 AWARD

Elizabeth Brunk, PhD

The University of North Carolina at Chapel Hill

Linking Structural DNA Variation to Therapeutic Response and Resistance in HER2-Mutated NSCLC



Pinar Özden Eser, PhD

Broad Institute of MIT and Harvard

Identifying actionable targets to improve response to therapy among patients with HER2-driven NSCLC



LCRF | BAYER RESEARCH HER2 AWARD

Sarah Goldberg, MD, MPH

Yale School of Medicine

Stratifying and Personalizing for HER2 Mutated Lung Cancers



Xiuning Le, MD, PhD

University of Texas MD Anderson Cancer Center

Characterization of HER2 Mutations' Sensitivity to Sevabertinib & Development of Novel Combination Strategies to Overcome Resistance to Current HER2 Therapies



Paul Stockhammer, MD, PhD

Yale University

Molecular determinants of tumor growth and therapeutic response in ERBB2-mutant lung cancer



ICRF-LCRF PROJECT GRANT

Joel Yisraeli, PhD

Hebrew University of Jerusalem

Treating Lung and Colorectal Carcinomas by Targeting IGFBP1

